NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ADMA

Adma Biologics Inc

Jul 01 • 04:00PM ET

17.88

Dollar change -0.33
Percentage change -1.81	%

Healthcare • Biotechnology • USA • NASD

Peers: CSL GRFS BAX BMY PFE JNJ MRK LLY COHR GILD

| Held by: IJR VTI IWM VXF XBI IJT IWO SPSM XSMO IBB

Scroll to Statements

Index	RUT	P/E	21.18	EPS (ttm)	0.84	Insider Own	3.44%	Shs Outstand	238.53M	Perf Week	0.17%
Market Cap	4.27B	Forward P/E	19.02	EPS next Y	0.94	Insider Trans	-6.26%	Shs Float	230.52M	Perf Month	-9.88%
Enterprise Value	4.28B	PEG	0.54	EPS next Q	0.14	Inst Own	86.39%	Short Float	5.99%	Perf Quarter	-9.88%
Income	206.77M	P/S	9.29	EPS this Y	27.15%	Inst Trans	0.16%	Short Ratio	3.80	Perf Half Y	-0.06%
Sales	459.38M	P/B	11.42	EPS next Y	51.61%	ROA	48.01%	Short Interest	13.81M	Perf YTD	4.26%
Book/sh	1.57	P/C	59.60	EPS next 5Y	39.37%	ROE	78.45%	52W High	25.67 -30.35%	Perf Year	63.29%
Cash/sh	0.30	P/FCF	47.09	EPS past 3/5Y	- -	ROIC	45.52%	52W Low	10.21 75.12%	Perf 3Y	821.65%
Dividend Est.	-	EV/EBITDA	26.75	Sales past 3/5Y	74.01% 70.79%	Gross Margin	52.53%	Volatility	4.04% 4.27%	Perf 5Y	527.37%
Dividend TTM	-	EV/Sales	9.31	EPS Y/Y TTM	5113.71%	Oper. Margin	33.10%	ATR (14)	0.87	Perf 10Y	112.60%
Dividend Ex-Date	-	Quick Ratio	3.36	Sales Y/Y TTM	62.22%	Profit Margin	45.01%	RSI (14)	37.38	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	6.58	EPS Q/Q	46.08%	SMA20	-7.95%	Beta	0.43	Target Price	32.33
Payout	0.00%	Debt/Eq	0.22	Sales Q/Q	40.22%	SMA50	-12.84%	Rel Volume	0.66	Prev Close	18.21
Employees	685	LT Debt/Eq	0.22	Earnings	May 07 AMC	SMA200	-5.23%	Avg Volume	3.63M	Price	17.88
IPO	Oct 17, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-11.22% -1.38%	Trades		Volume	2,390,052	Change	-1.81%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-23	Resumed	Raymond James	Strong Buy	$5
Oct-13-22	Initiated	Mizuho	Buy	$5
Nov-11-21	Upgrade	Raymond James	Outperform → Strong Buy	$5
Nov-09-21	Initiated	Cantor Fitzgerald	Overweight	$4.50
Jun-04-19	Initiated	Jefferies	Buy	$8
Apr-15-19	Reiterated	H.C. Wainwright	Buy	$10 → $13
Feb-07-19	Resumed	H.C. Wainwright	Buy	$10
Dec-11-17	Reiterated	Maxim Group	Buy	$13 → $8
Nov-14-17	Upgrade	Raymond James	Mkt Perform → Outperform
Jan-23-17	Upgrade	Maxim Group	Hold → Buy	$13
Aug-01-16	Downgrade	Maxim Group	Buy → Hold
Jul-25-16	Reiterated	Maxim Group	Buy	$24 → $14
May-13-15	Reiterated	Maxim Group	Buy	$18 → $24
Dec-08-14	Initiated	Oppenheimer	Outperform	$20
Dec-01-14	Reiterated	Maxim Group	Buy	$16 → $18

Show Previous Ratings

Jun-27-25 05:50PM	Adma Biologics (ADMA) Stock Drops Despite Market Gains: Important Facts to Note (Zacks)
10:56AM	Implied Volatility Surging for ADMA Biologics Stock Options (Zacks)
08:11AM	Will Strong Asceniv Sales Drive ADMA Biologics Further? (Zacks)
Jun-25-25 08:54AM	ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? (Zacks)
Jun-24-25 10:21AM	ADMA Biologics (ADMA) Drops 14.7% W/W as 3 Execs Unload Portfolios (Insider Monkey)
05:50PM	Loading…
Jun-20-25 05:50PM	Here's Why Adma Biologics (ADMA) Fell More Than Broader Market (Zacks)
Jun-19-25 02:05PM	ADMA Biologics (ADMA) Drops for 5th Consecutive Day - Here's Why (Insider Monkey)
Jun-16-25 01:06PM	ADMA Looks to Expand Asceniv's Label: Will This Boost Sales? (Zacks)
Jun-13-25 01:57PM	CoreWeave Leads Four Stocks Near Buy Points; One Is Also An Nvidia Partner (Investor's Business Daily)
Jun-11-25 06:20AM	Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now? (Zacks)
Jun-06-25 04:00PM	This IBD 50 Biotech's Got 'Rhythm' And Flashes 3 Telltale Clues (Investor's Business Daily)
03:13PM	Kymera Therapeutics Stock Earns 92 RS Rating (Investor's Business Daily)
10:40AM	ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold? (Zacks)
Jun-05-25 06:20AM	Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar? (Zacks)
May-28-25 10:01AM	ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy? (Zacks)
08:34AM	Loading…
May-22-25 08:34AM	Are Options Traders Betting on a Big Move in ADMA Biologics Stock? (Zacks)
May-09-25 01:29PM	Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging (Zacks) -5.75%
11:12AM	Pacira BioSciences Q1 Earnings Beat, Revenues Miss Estimates (Zacks)
10:41AM	RCKT's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
May-08-25 01:26PM	ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock? (Zacks) -10.21%
12:38PM	Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains (Zacks)
12:25PM	Why IBD 50's No. 2 Stock, ADMA Biologics, Just Plummeted By Double Digits (Investor's Business Daily)
10:58AM	Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:43AM	Apellis' Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
10:40AM	Acadia Q1 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
03:30AM	ADMA Biologics Inc (ADMA) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
May-07-25 11:05PM	ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:25PM	Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates (Zacks)
04:30PM	Adma Biologics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
10:45AM	Ultragenyx's Q1 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:29AM	Novo Nordisk Q1 Earnings Match Estimates, Revenues Rise Y/Y, Stock Up (Zacks)
10:00AM	Here are the major earnings after the close today (Seeking Alpha)
07:40AM	CRISPR Therapeutics Q1 Earnings and Sales Miss Estimates, Stock Tanks (Zacks)
May-06-25 01:37PM	Krystal Biotech Q1 Earnings and Sales Miss Estimates, Stock Down (Zacks)
01:12PM	CORT's Q1 Earnings In Line With Estimates, Revenues Lag, Shares Fall (Zacks)
12:50PM	3 Mid-Cap Medical Stocks Outperforming the Market (MarketBeat)
11:59AM	VRTX's Q1 Earnings Lag Estimates, 2025 Revenue View Tightened (Zacks)
11:07AM	Zoetis Q1 Earnings & Revenues Beat Estimates, '25 Outlook Raised (Zacks)
09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
09:17AM	RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates (Zacks)
May-05-25 08:25AM	Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus (Zacks)
May-02-25 05:45PM	Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know (Zacks)
01:18PM	FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls (Zacks)
12:21PM	Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings (Zacks)
11:10AM	Alkermes' Q1 Earnings and Revenues Fall Short of Estimates (Zacks)
07:53AM	Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates (Zacks)
May-01-25 01:22PM	Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings? (Zacks)
10:40AM	Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
09:48AM	Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down (Zacks)
09:40AM	Has ADMA Biologics (ADMA) Outpaced Other Medical Stocks This Year? (Zacks)
09:00AM	Investors Heavily Search ADMA Biologics Inc (ADMA): Here is What You Need to Know (Zacks)
08:50AM	Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why (Zacks)
07:57AM	UTHR Q1 Earnings & Revenues Beat Estimates on Higher Tyvaso Sales (Zacks)
04:51AM	The Zacks Analyst Blog Highlights ADMA, FirstCash, Stride, Life Time Group and National Fuel Gas (Zacks)
Apr-30-25 12:17PM	Sage Therapeutics' Q1 Earnings Miss Mark, Revenue Rise Y/Y (Zacks)
09:07AM	Repligen's Q1 Earnings Beat Estimates, Revenues Surge Y/Y (Zacks)
08:24AM	These 5 Buy-Ranked Mid-Cap Stocks Are Flying High Year to Date (Zacks)
07:00AM	ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-29-25 05:50PM	Adma Biologics (ADMA) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
08:45AM	Global Artificial Intelligence Influence on Diabetic Retinopathy Market Expected to See Significant Growth (GlobeNewswire)
02:01AM	Why ADMA Biologics, Inc. (ADMA) Surged on Monday (Insider Monkey)
Apr-28-25 04:05PM	IBD 50's Top Seed, ADMA, Just Rocketed On A New FDA Approval (Investor's Business Daily) +12.12%
07:00AM	ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process (GlobeNewswire)
Apr-25-25 01:52PM	Tech Stocks Reclaim Dominance In Elite List Led By Palantir (Investor's Business Daily)
10:41AM	GILD Down on Q1 Earnings and Sales Miss, Oncology Sales Decline (Zacks)
Apr-24-25 11:54AM	BMY Beats on Q1 Earnings and Sales, Raises 2025 Outlook (Zacks)
Apr-23-25 08:48PM	ADMA Biologics, Inc. (ADMA): Among Takeover Rumors Hedge Funds Are Buying (Insider Monkey)
06:14PM	Is ADMA Biologics, Inc. (ADMA) the Best Multibagger Stock to Buy According to Billionaires? (Insider Monkey)
05:50PM	Adma Biologics (ADMA) Gains But Lags Market: What You Should Know (Zacks)
Apr-22-25 01:28AM	Why ADMA Biologics Inc. (ADMA) Performed Worst On Monday? (Insider Monkey) +8.91%
Apr-17-25 05:50PM	Adma Biologics (ADMA) Beats Stock Market Upswing: What Investors Need to Know (Zacks) -7.84%
09:17AM	GSK's Pentavalent Meningococcal Jab Recommended for Use by ACIP (Zacks)
09:09AM	ADMA Biologics (ADMA): Among Louis Navellier's New Stock Picks (Insider Monkey)
Apr-16-25 09:48AM	MURA Soars as it Explores Strategic Options Post Cancer Study Failures (Zacks)
09:30AM	Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True? (Zacks)
08:52AM	DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up (Zacks)
06:45AM	Why ADMA Biologics, Inc. (ADMA) Skyrocketed On Tuesday? (Insider Monkey)
Apr-15-25 12:27PM	VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study (Zacks) +5.93%
10:42AM	Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag (Zacks)
09:40AM	Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? (Zacks)
09:35AM	Adma Biologics (ADMA) Just Overtook the 20-Day Moving Average (Zacks)
09:18AM	Ironwood Shares Tank on Regulatory Update for Apraglutide (Zacks)
08:59AM	Adma Biologics (ADMA) Moves 7.8% Higher: Will This Strength Last? (Zacks)
08:50AM	Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
12:41AM	Why ADMA Biologics Inc. (ADMA) Skyrocketed On Monday? (Insider Monkey)
Apr-14-25 09:51AM	Roche Gets Nod for Expanded Use of Columvi in Lymphoma in Europe (Zacks) +7.78%
Apr-11-25 01:17PM	NVS Plans to Invest $23B in US Manufacturing Sites Amid Tariff Threat (Zacks)
11:57AM	KROS Initiates Exploring Strategic Alternatives, Stock Gains 18.5% (Zacks)
11:49AM	Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate (Zacks)
Apr-10-25 10:53AM	PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose (Zacks)
09:58AM	ANIX Gets New Patent for Breast Cancer Vaccine Technology, Stock Up (Zacks)
Apr-09-25 10:01AM	RXRX Doses First Patient in Early-Stage B-Cell Lymphomas Study (Zacks) +8.57%
Apr-08-25 05:10PM	Nurix Therapeutics, Inc. (NRIX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
03:42PM	Rhythm Pharmaceuticals Stock Earns RS Rating Upgrade (Investor's Business Daily)
11:29AM	PCRX Stock Soars on Exparel Patent Settlement With Generic Players (Zacks)
11:21AM	RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study (Zacks)
09:56AM	Viatris to Pay $335 Million for Settlement of Opioid-Related Claims (Zacks)
Apr-07-25 01:22PM	5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025 (Zacks)

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Grossman Adam S	President and CEO	Jun 16 '25	Option Exercise	5.40	15,000	81,000	2,064,850	Jun 18 09:00 PM
Grossman Adam S	President and CEO	Jun 16 '25	Sale	20.81	21,000	437,010	2,043,850	Jun 18 09:00 PM
ELMS STEVE	Director	Jun 13 '25	Option Exercise	3.43	332,680	1,140,763	420,010	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 16 '25	Sale	20.24	194,749	3,941,720	87,330	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 13 '25	Sale	20.82	137,931	2,871,723	282,079	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 12 '25	Sale	21.69	92,941	2,015,890	2,031,730	Jun 16 09:00 PM
ELMS STEVE	Director	Jun 12 '25	Proposed Sale	21.87	425,621	9,308,331		Jun 12 08:33 PM
Guiheen Lawrence P.	Director	Jun 09 '25	Sale	20.96	20,000	419,200	94,830	Jun 11 09:00 PM
Grossman Jerrold B	Director	Jun 09 '25	Option Exercise	5.00	10,000	50,000	488,194	Jun 10 09:00 PM
Grossman Jerrold B	Director	Jun 09 '25	Sale	21.31	10,000	213,100	478,194	Jun 10 09:00 PM
Grossman Jerrold B	Director	Jun 09 '25	Proposed Sale	20.61	10,000	206,100		Jun 09 09:00 PM
Lawrence P Guiheen Rev Tr DTD	Director	Jun 04 '25	Proposed Sale	20.75	20,000	415,000		Jun 04 01:52 PM
Guiheen Lawrence P.	Director	May 21 '25	Option Exercise	5.96	7,779	46,363	122,609	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 22 '25	Option Exercise	5.96	1,221	7,277	116,051	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 21 '25	Sale	20.32	7,779	158,069	114,830	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 22 '25	Sale	20.12	1,221	24,567	114,830	May 23 09:00 PM
Guiheen Lawrence P.	Director	May 21 '25	Proposed Sale	20.44	9,000	183,960		May 21 09:36 PM
Grossman Adam S	President and CEO	May 15 '25	Option Exercise	5.40	15,000	81,000	2,070,850	May 16 09:00 PM
Grossman Adam S	President and CEO	May 15 '25	Sale	19.45	21,000	408,450	2,049,850	May 16 09:00 PM
Grossman Adam S	President and CEO	Apr 15 '25	Option Exercise	5.40	15,000	81,000	2,076,850	Apr 16 09:00 PM
Grossman Adam S	President and CEO	Apr 15 '25	Sale	21.46	21,000	450,660	2,055,850	Apr 16 09:00 PM
Grossman Adam S	President and CEO	Mar 19 '25	Option Exercise	5.40	15,000	81,000	2,082,850	Mar 21 09:00 PM
Grossman Adam S	President and CEO	Mar 19 '25	Sale	18.92	21,000	397,320	2,061,850	Mar 21 09:00 PM
Grossman Adam S	Director and Officer	Mar 19 '25	Proposed Sale	18.71	84,000	1,571,640		Mar 19 09:40 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Jan 30 '25	Option Exercise	10.80	5,000	54,000	449,587	Feb 03 09:00 PM
ELMS STEVE	Director	Nov 27 '24	Option Exercise	10.80	9,000	97,200	2,124,671	Dec 02 09:02 PM
Tade Brad L.	CFO and Treasurer	Nov 22 '24	Sale	21.15	15,000	317,250	199,433	Nov 22 09:05 PM
Grossman Adam S	President and CEO	Nov 22 '24	Sale	21.10	48,967	1,033,204	1,989,007	Nov 22 09:05 PM
Grossman Adam S	Director and Officer	Nov 22 '24	Proposed Sale	21.30	48,967	1,042,997		Nov 22 09:00 PM
Tade Brad L.	Officer	Nov 22 '24	Proposed Sale	21.30	15,000	319,500		Nov 22 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Option Exercise	10.80	9,000	97,200	162,941	Sep 11 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Sale	18.47	9,000	166,189	153,941	Sep 11 09:00 PM
Guiheen Lawrence P.	Director	Sep 09 '24	Proposed Sale	16.26	9,000	146,340		Sep 09 09:00 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Aug 30 '24	Option Exercise	3.87	24,150	93,526	473,238	Aug 30 09:05 PM
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	Aug 30 '24	Sale	16.90	24,150	408,050	449,088	Aug 30 09:05 PM
Grossman Jerrold B	Director	Aug 29 '24	Option Exercise	4.28	136,861	585,871	604,166	Aug 30 09:02 PM
Grossman Jerrold B	Director	Aug 29 '24	Sale	17.27	136,861	2,363,932	467,305	Aug 30 09:02 PM
Kestenberg-Messina Kaitlin M.	Officer	Aug 30 '24	Proposed Sale	17.22	24,150	415,863		Aug 30 09:00 PM
Grossman Jerrold B	Director	Aug 29 '24	Proposed Sale	17.24	136,861	2,359,484		Aug 29 09:26 PM
Grossman Adam S	President and CEO	Aug 26 '24	Option Exercise	6.84	236,889	1,619,466	2,296,615	Aug 27 09:22 PM
Grossman Adam S	President and CEO	Aug 27 '24	Option Exercise	3.30	389,356	1,283,725	2,449,082	Aug 27 09:22 PM
Grossman Adam S	President and CEO	Aug 27 '24	Sale	17.29	389,356	6,732,900	2,059,726	Aug 27 09:22 PM
Grossman Adam S	President and CEO	Aug 26 '24	Sale	17.69	236,889	4,191,088	2,059,726	Aug 27 09:22 PM
KWON YOUNG	Director	Aug 23 '24	Sale	18.26	60,000	1,095,600	241,441	Aug 27 09:00 PM
Grossman Adam S	Officer	Aug 26 '24	Proposed Sale	18.20	626,245	11,397,659		Aug 26 09:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADMA

Adma Biologics Inc

Upgrade your FINVIZ experience